Market Place
Sourcing Support
Eledon Pharmaceuticals Highlights & Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Eledon Pharma to Attend Guggenheim Healthcare Conferenc
06 Nov 2024 //
GLOBENEWSWIRE
Eledon Reports Positive Data on Tegoprubart in Type 1 Diabetes
29 Oct 2024 //
GLOBENEWSWIRE
Eledon Prices $85 Million Offering of Common Stock and Warrants
29 Oct 2024 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11 Sep 2024 //
GLOBENEWSWIRE
Eledon Completes Enrollment In Tegoprubart BESTOW Trial
04 Sep 2024 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
14 Aug 2024 //
GLOBENEWSWIRE
Eledon Updates Enrollment For Phase 2 BESTOW Trial
29 Jul 2024 //
GLOBENEWSWIRE
Eledon To Participate In Leerink Partners Therapeutics Forum
02 Jul 2024 //
GLOBENEWSWIRE
Eledon`s Tegoprubart Kidney Transplant Prevention Phase 1b Update
03 Jun 2024 //
GLOBENEWSWIRE
Eledon Kidney Transplant Tegoprubart Data At Transplant Congress
09 May 2024 //
GLOBENEWSWIRE
Eledon Pharmac Reports First Quarter 2024 Operating and Financial Results
09 May 2024 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
07 May 2024 //
GLOBENEWSWIRE
Eledon Updates On Tegoprubart For Transplant Rejection Prevention
07 May 2024 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Reports Q4 & FY23 Operating and Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW
25 Mar 2024 //
GLOBENEWSWIRE
Eledon Announces Tegoprubart in First-ever Transplant from a Pig to a Human
21 Mar 2024 //
GLOBENEWSWIRE
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Feb 2024 //
GLOBENEWSWIRE
Eledon Pharma Highlights Recent Business Milestones and Provides 2024 Outlook
04 Jan 2024 //
GLOBENEWSWIRE
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Dec 2023 //
GLOBENEWSWIRE
Eledon to Present at Noble Capital Markets` Emerging Growth Equity Conference
29 Nov 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
08 Nov 2023 //
GLOBENEWSWIRE
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart
02 Nov 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Appointed Eliezer Katz as CMO
23 Oct 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present Data from Phase 1b Trial of Tegoprubart
13 Oct 2023 //
GLOBENEWSWIRE
Eledon Appoints Dr. Allan Douglas Kirk to Board of Directors
02 Oct 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody
25 Sep 2023 //
GLOBENEWSWIRE
Eledon to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
Eledon Appoints Industry Veteran James Robinson to its Board of Directors
11 Sep 2023 //
GLOBENEWSWIRE
Eledon Announces Publication of Data Showing Treatment with Tegoprubart
06 Sep 2023 //
GLOBENEWSWIRE
Eledon Announces First Participant Dosed in Phase 2 Trial Evaluating Tegoprubart
05 Sep 2023 //
GLOBENEWSWIRE
Eledon Announces Dosing of 10th Patient in Phase 1b Trial Evaluating Tegoprubart
16 Aug 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Eledon Pharma Reports First Quarter 2023 Operating and Financial Results
11 May 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Report 1Q 2023 FYR on Thursday, May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Announces up to $185 Million Financing
01 May 2023 //
GLOBENEWSWIRE
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart
31 Mar 2023 //
GLOBENEWSWIRE
Eledon Pharma Reports 4Q and Full-Year 2022 Operating and Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart
23 Mar 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Report4Q & 2022 FYR on Thursday, March 30, 2023
23 Mar 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
eGenesis and Eledon Announce Collaboration for Use of Tegoprubart
09 Jan 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Provides Business and Pipeline Updates
09 Jan 2023 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Reports 3Q 2022 Operating and Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Report 3Q FYR on Monday, November 14, 2022
03 Nov 2022 //
GLOBENEWSWIRE
Eledon Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
24 Oct 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Participate in Two Upcoming Conferencess
03 Oct 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
22 Sep 2022 //
GLOBENEWSWIRE
Eledon Receives FDA Clearance of IND Application to Evaluate Tegoprubart
06 Sep 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
29 Aug 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals Reports 2Q 2022 Operating and Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Eledon Pharma Receives FDA Clearance of IND Application to Evaluate Tegoprubart
01 Aug 2022 //
GLOBENEWSWIRE
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jun 2022 //
GLOBENEWSWIRE
Eledon Bags ODD for Tegoprubart for Prevention of Allograft Rejection
09 Jun 2022 //
GLOBENEWSWIRE
Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Eledon Announces Positive Topline Results from PIIa Trial of Tegoprubart in ALS
31 May 2022 //
GLOBENEWSWIRE
Eledon Pharma Reports First Quarter 2022 Operating and Financial Results
12 May 2022 //
GLOBENEWSWIRE
